<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Remicade, a chimeric human-murine monoclonal antibody capable of neutralizing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha was given to 37 low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) patients in two cohorts; 5 and 10 mg/kg intravenously every 4 weeks for 4 cycles </plain></SENT>
<SENT sid="1" pm="."><plain>Median age was 68 years, 33 had primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 14 had <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), 14 RA with ringed sideroblasts, 9 RA with excess blasts </plain></SENT>
<SENT sid="2" pm="."><plain>Nine patients stopped therapy prior to completing 4 cycles, 3 from cohort 1 and 6 from cohort 2 and response was evaluated using the International Working Group criteria in 28 patients who completed the 4 cycles </plain></SENT>
<SENT sid="3" pm="."><plain>Six patients showed disease progression, 14 had stable disease and 8 showed hematologic responses, 3/15 (20%) in cohort 1 and 5/13 (38%) in cohort 2 </plain></SENT>
<SENT sid="4" pm="."><plain>Two patients had multi-lineage responses, 2 had &gt; 100% increase in absolute neutrophils, 1 had &gt; 1 gm/dl increase in <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, 1 had reduction in blasts from 7% to 1%, and 2 had minor cytogenetic responses (&gt; 50% reduction in + 8 and 20q-metaphases respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>We conclude that Remicade may have a variety of activities in low risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, is well tolerated with a high patient compliance, and may be considered for combination therapy in the future </plain></SENT>
</text></document>